Materials and Methods

Registry Design and Participants
Participants were enrolled between September 2010 and January 2012 at 50 PAH centers across the United States, all of which received institutional review board approval. Patients were eligible if they had been diagnosed with PAH (group 1 pulmonary hypertension) and were parenteral-naive or parenteral-transitioned from another formulation of epoprostenol or treprostinil therapy to RTS-Epo. Patients were followed for a maximum of 1 year or until discontinuation of RTS-Epo, withdrawal of consent, loss to follow-up, death, or end of study.
Data Collection
Patient data were collected at enrollment and quarterly intervals (months 3, 6, 9, and 12) ( e- Table 1 ) . No treatments or assessments were mandated by the protocol. Clinical characteristics, medical history, and comorbid conditions, including pulmonary function tests, echocardiogram, New York Heart Association functional class (NYHA FC) evaluation, and 6-min walk distance (6MWD) were collected using the most recent clinical visits, hospitalization, and/or telephone contacts. Th e treating physician determined renal insuffi ciency by selecting a checkbox in the electronic case report form. Among those patients who had a creatinine recorded, estimated glomerular fi ltration rate was computed. Dosing regimen and titration schedule for RTS-Epo and concomitant PAH medications were also collected quarterly.
Outcomes
Clinical outcomes from PROSPECT included demographics and disease characteristics of patients receiving RTS-Epo. Safety outcomes included all-cause deaths and hospitalizations and blood stream infections (BSIs). All outcomes were stratifi ed by patient demographics and disease characteristics. Hospitalizations were assigned by the treating physician as related to the use of RTS-Epo, due to PAH, both, or neither. Reports of BSIs leading to hospitalization or death were also collected. Hospitalizations for initiation of RTS-Epo were not collected. Hospitalizations were coded using the MedDRA coding dictionary (version 14.0).
Deaths were collected during the course of the study. Patients who discontinued the study for any reason were censored on the date of discontinuation.
Statistical Analysis
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In Th e Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry), the 1-year, 3-year, 5-year, and 7-year survival rates from time of diagnostic right-sided heart catheterization in a more diverse group of patients with PAH were 85%, 68%, 57%, and 49%, respectively. 3 Hospitalization has been suggested as an indicator of poor survival; death, lung transplantation, and hospitalization have been identifi ed as clinical effi cacy measures in PAH clinical research. 4 Additionally, in a study evaluating definitions of clinical worsening as a predictor of proximate (within 1 year) risk for subsequent major events (ie, death, transplantation, or atrial septostomy), hospitalization was independently associated with poor survival: the 1-year survival rate in patients hospitalized was only 71.4% Ϯ 1.5%. 5 Epoprostenol is an IV synthetic prostacyclin shown to improve exercise capacity and World Health Organization (WHO) functional class, while prolonging survival. 1, [6] [7] [8] [9] Epoprostenol remains the recommended treatment of the most advanced cases of PAH. 10 Th ere are limited data documenting the long-term rates of hospitalization and survival beyond 12 weeks with epoprostenol. Prior studies of survival in patients on epoprostenol have been limited to patients with primary pulmonary hypertension (PPH, now known as IPAH) in an era where prostacyclins were the only available therapy, and are limited to single-center cohort studies. 1, 8, 9, 11 Epoprostenol for injection (Veletri, prolonged room temperature stable-epoprostenol [RTS-Epo]) is a US Food and Drug Administration (FDA)-approved formulation of epoprostenol that has improved stability over the standard formulation of epoprostenol at room temperature. 12 Th e Registry to Prospectively Describe the Use of RTS-Epo in Patients with Pulmonary Arterial Hypertension (PROSPECT) is a multicenter, prospective, observational registry of patients who were prescribed RTS-Epo. Th e registry longitudinally describes the modern-day course of patients with PAH treated with epoprostenol (RTS-Epo), by evaluating a broad range of clinical and patient-reported outcomes for 1 year aft er enrollment. Th e objective of this analysis is to assess the baseline characteristics and the risk of hospitalization and mortality in this cohort.
Results
Patient Demographic and Clinical Characteristics
A total of 354 patients enrolled in PROSPECT; 18 did not have PAH. Th us, the analytic cohort included the remaining 336 patients. Patient demographics and comorbid conditions at enrollment are summarized in Table 1 . Th e clinical characteristics of all patients, and by prostacyclin history at enrollment, are summarized in Table 2 . Patient characteristics at baseline by hospitalization status, survival status (over 1 year of follow-up), and sex are summarized in Table 3 . Th e most common reason for initiation to RTS-Epo was PAH progression in the parenteral-naive group (57.1%) and other in the parenteral-transitioned group (42.3%) ( e- Table 2 ). Among the 18 non-group 1 patients, chronic thromboembolic pulmonary hypertension and sarcoidosis each represented approximately one-third ( Table 4 ) . Concomitant PAH medications at start of RTS-Epo in the non-group 1 patients are summarized in Table 2 . A summary of concomitant medications at enrollment for the patients in the non-WHO group 1 are summarized in Table 4 .
Patients requiring hospitalization in the fi rst year were more likely to be men, have PAH associated with connective tissue disease (CTD), be NYHA FC III or IV, have a lower mean 6MWD, have a higher mean REVEAL Registry Risk Score, and were more likely to be parenteral prostanoidnaive compared with patients who were not hospitalized.
Patients who died during the study were older, were more likely to have PAH associated with CTD, be NYHA FC IV, have a lower mean 6MWD, have a higher mean REVEAL Registry Risk Score, and were more likely to be parenteral prostanoid-naive compared with patients who survived.
Men comprised about 20% of the surviving patients in PROSPECT; 43.1% of the deaths occurred in men. Men were more likely than women to have familial PAH, congenital PAH, or PAH associated with portopulmonary hypertension. A higher mean REVEAL Registry Risk Score was observed in men, who were also more likely to be parenteral prostanoid-naive at enrollment compared with women.
Hospitalizations
A total of 296 on-study all-cause hospitalizations occurred in 157 patients (150 were parenteralnaive patients and 146 were parenteral-transitioned continuous variables. Th e REVEAL Risk Score calculator was included, which incorporates 19 variables that predict 1-year survival in patients with PAH. 13 Patient characteristics were summarized by hospitalization status (hospitalized vs not hospitalized), survival status (survived vs died), and sex. Rates of on-study hospitalizations (defined as those with a date of hospital admission after the date of enrollment) per 1,000 patient-days were calculated for all patients and by prostacyclin history (parenteral-naive or parenteraltransitioned).
Survival over the 1 year of follow-up was estimated based on KaplanMeier curves. For patients who died during follow-up, length of survival was calculated from the date of enrollment to the date of death reported. Patients who did not die were censored at the earlier of their date of discontinuation from the study or the date of the last data collection. Freedom from hospitalization, survival esti mates, and SEs were summarized for all patients, and by prostacyclin history, sex, and chronic renal insuffi ciency (CRI). Risk-adjusted hazard ratios were computed from a multivariable Cox regression model. Includes n 5 119 patients who were prostacyclin-naive, n 5 26 patients who transitioned from an inhaled prostacyclin, and n 5 2 patients who transitioned from an oral prostacyclin at study entry. b Includes n 5 180 patients who transitioned from epoprostenol and n 5 9 patients who transitioned from treprostinil at study entry. c The initial dose at time of initiation of prolonged RTS-Epo, which may not be at enrollment.
patients). The median length of stay was longer for parenteral-naive patients than for parenteraltransitioned patients (median 5.0, interquartile range: 3.0, 9.0 vs median 4.0, interquartile range: 2.0, 7.0, respectively).
Of the hospitalized patients (n 5 157), 77 (49.0%) were not rehospitalized, 51 (32.5%) were rehospitalized once, 12 (7.6%) were rehospitalized twice, and 17 (10.8%) were rehospitalized three or more times during the 1-year follow-up. There were no differences in frequencies of rehospitalization between parenteral-naive and parenteral-transitioned groups.
Rates and All Causes of Hospitalizations
The overall rate of all-cause hospitalizations in group 1 patients with PAH was 2.8 per 1,000 patient-days (3.3 per 1,000 patient-days in parenteral-naive patients and 2.4 per 1,000 patient-days in parenteral-transitioned patients [ Fig 1 ] ). Hospitalization rates for the nongroup 1 patients was 2.0 per 1,000 patient-days.
All causes of hospitalization with at least fi ve occurrences are shown in Table 5 . The most common causes of hospitalizations were infections (51) and heart failures (48). Th irty-seven percent of hospitalizations were categorized as being related to PAH (44% in the parenteralnaive group and 31% in the parenteral-transitioned group). 
Freedom From Hospitalization
Th e 1-year freedom from hospitalization estimate ( Ϯ SE) for the n 5 336 group 1 patients was 51.0% Ϯ 2.8%. Th e freedom from hospitalization estimate for patients who were parenteral-naive at enrollment was 42.8% Ϯ 4.3% compared with 57.1% Ϯ 3.7% for parenteral-transitioned patients ( P 5 .002) ( Fig 2A ) . Th e freedom from hospitalization estimate for men was 38.3% Ϯ 5.9%; for women, it was 54.6% Ϯ 3.2% ( P , .015) ( Fig 2B ) . Patients with Table 2 legend for expansion of other abbreviations. a Chronic thromboembolic pulmonary hypertension (5), sarcoidosis (6), carcinoid syndrome (1), pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (1), lung disease (1), pulmonary hypoplasia, giant omphalocele (1), left-sided heart disease/morbid obesity (1), post-liver transplant pulmonary hypertension (1), and pulmonary hypertension due to underlying infl ammatory myopathy (1). CRI had a lower freedom from hospitalization compared with patients without CRI (17.0% Ϯ 8.4% vs 53.7% Ϯ 2.9%; P , .001).
Survival Estimates
Th e 1-year survival estimate ( Ϯ SE) for all patients in PROSPECT was 84.0% Ϯ 2.1%. Th e 1-year survival estimate for patients who were classifi ed as parenteral-naive at baseline was lower than the survival estimate for patients who were parenteral-transitioned (79.4% Ϯ 3.4% vs 87.7% Ϯ 2.5%; P 5 .038) ( Fig 3A ) . Th e 1-year survival estimate in men was lower than in women (71.0% Ϯ 5.2% vs 88.0% Ϯ 2.1%; P , .001) ( Fig 3B ) . A sensitivity analysis using an estimated glomerular fi ltration rate cutpoint rather than the qualitative defi nition of CRI produced similarly signifi cant results. A multivariate Cox regression model of group 1 patients confi rmed that sex and CRI were independent risk factors, whereas there was no diff erences between naive and transition patients aft er adjusting for diff erences in risk profi le. ( Table 6 ) . Th e 1-year survival estimate was lower than in patients without CRI (63.4% Ϯ 9.3% vs 86.0% Ϯ 2.0%; P , .001). Th e 1-year survival estimate in the non-group 1 patients was 88.9% Ϯ 7.4%.
Discussion
PROSPECT is the fi rst modern-day registry, to our knowledge, to assess outcomes in a large series of patients with PAH taking epoprostenol and examine outcomes by prostacyclin history, risk of hospitalization, and mortality in patients in a real-world setting. Th e strengths of the study include the size of the cohort, broad inclusion criteria, and 1-year follow-up.
Th is analysis shows a high burden of illness in these patients, with an overall 1-year probability of survival of 84% Ϯ 2.1% and only about 50% remaining free of hospitalization at 1 year. Specifi c subgroups within PROSPECT were at higher risk of both hospitalization and mortality compared with their counterparts, in particular, patients who were parenteral-naive at enrollment, male patients, and patients with CRI. Mean REVEAL Registry Risk Scores were higher in these subgroups, reconfi rming the applicability of the score to this patient population. 13 An interesting fi nding is the large proportion of hospitalizations due to various comorbid conditions which could be explained by patients with PAH living longer and developing unrelated or unrecognized complications of PAH.
Survival in patients with PAH in the modern treatment era has improved compared with previously observed Figure 2 -A 
, B, Freedom from hospitalization at 1 y by prostacyclin history (A) and sex (B).
survival. However, as outcomes among PAH subpopulations vary substantially, 14 continuing rigorous disease management of PAH is important. Patient survival appears to be related to the ability of the right ventricle to adapt to the chronically elevated pulmonary artery pressure. 8 Hospitalizations have been recognized as not only an important outcome measure when assessing clinical effi cacy in PAH trials, but also an important prognostic factor in patients with PAH. 4, 5 While PROSPECT confirms that use of RTS-Epo is associated with greater survival rates than that historically expected, rates of hospitalization are still high for patients with the disease. Overall survival of patients taking RTS-Epo was comparable to other studies of epoprostenol. 1, 8, 9 However, these older studies were limited single-site studies of patients with PPH and did not include higher-risk patients from associated PAH subgroups.
Survival in patients with PPH treated with epoprostenol depends on disease severity. 9 In PROSPECT, patients who were parenteral-naive at baseline had worse Figure 3 -A 
, B, One-y survival by prostacyclin history (A) and sex (B).
outcomes compared with patients who were parenteraltransitioned. Th ese results support fi ndings that earlier initiation of prostacyclin therapy or more aggressive therapy should be considered. 15 A study found that treatment with oral therapy or parenteral prostacyclin as initial strategy was associated with a high survival rate in patients who were WHO functional class III and whose PAH was idiopathic, familial, or anorexigen associated. 16 Th e authors suggest that the more potent prostacyclins be reserved for high-risk patients, such as those with evidence of disease progression or those with treatment failure. It should be noted that fi ndings in this analysis may refl ect survivor bias in those already on parenteral therapy or the more critical nature of the disease in patients who are parenteral-naive.
Sex diff erences observed in this analysis are consistent with other studies. Although the incidence of PAH is higher in women, survival is lower in men. Th e 5-year survival rate from diagnosis in the REVEAL Registry was 52% in men compared with 62% in women. 17 It is unclear why women have a better survival rate than 
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